Copper tripeptide
GHK-Cu
GHK-Cu after one dose: 50% at ~4 h, 25% at 8 h, 12.5% at 12 h.
Drawn from the half-life in the app's model, ~4 h. The model's figures
- Compound
- GHK-Cu
- Symbol
- GHK
- Family
- Cosmetic and copper peptides
- Parts
- 14
- References
- 22
- Checked
- Last reviewed . Sources are listed below.
How Milligram users log it

15%The 3rd most tracked compound in Milligram: of people who track compounds in Milligram logged GHK-Cu in the last 90 days.
Schedule
Logged doses
Half of people logged between 1.5 and 2.5 mg per dose; the median was 2 mg.
Tracked alongside
The share of people logging GHK-Cu who also logged each.
From dose logs in the Milligram app, 90 days to 15 November 2026. Aggregated and anonymous. This describes what people recorded, not what anyone should take.
Overview
GHK-Cu is the copper(II) complex of the tripeptide glycyl-L-histidyl-L-lysine (GHK).2 Pickart and Margolina, in the International Journal of Molecular Sciences in 2018, describe GHK-Cu as "a small, naturally occurring tri-peptide present in human plasma that also can be released from tissues in case of an injury".1
A 2015 review by Pickart, Vasquez-Soltero and Margolina gives the plasma level of GHK as about 200 ng/mL at age 20, falling to 80 ng/mL by age 60, without stating the sex, method or number of people measured.3 A 2012 review by the same authors gives about 200 micrograms/liter in men aged 20 to 25 and 80 micrograms/liter at age 60 to 80.4
A 2026 systematic review by Najafi and colleagues in Archives of Internal Medicine Research states that "the clinical literature in humans remains thin and fragmented: most randomized trials are small, conducted on facial cosmetic creams".5 A second 2026 systematic review, by Mokhtar and colleagues in Aesthetic Surgery Journal, included 20 studies, 18 of them preclinical and 2 randomised controlled trials.6 Its authors write that the findings were "constrained by methodological variability and a limited number of well-designed clinical trials".6 The app grades the evidence quality for GHK-Cu as moderate, while Mateescu and colleagues write that "the clinical evidence remains sparse" and Najafi and colleagues call the human literature "thin and fragmented".2,5
On authorship, Najafi and colleagues state that "Approximately 35% of the GHK-Cu primary literature in the inclusion window includes Loren Pickart or Anna Margolina (Skin Biology Inc.) as an author", and that Pickart "held commercial interests in the field for decades".5 They add that the concentration of authorship "limits the independence of the evidence base".5
How it works
Copper binding
Pickart and colleagues reported in Nature in 1980 that the plasma tripeptide, labelled "glycyl-L-lysine (GHL)" in its published summary, "readily forms complexes with copper(II) and enhances the uptake of the metal into cultured hepatoma cells" (the HTC4 cell line).7
In cells and gene databases
In the study of Badenhorst and colleagues (Journal of Aging Science, 2016), human adult dermal fibroblasts were incubated with GHK-Cu at 0.01, 1 and 100 nM, and collagen and elastin production was significantly higher than in untreated cells at 96 hours, with an inverse dose-dependent response for collagen.8 MMP1 and MMP2 expression rose at the lowest concentration, TIMP1 at every concentration tested, and TIMP2 fell at higher concentrations.8
Pickart and Margolina report that 31.2% of human genes change by 50% or more in response to GHK, with expression increased in 59% of those genes and suppressed in 41%.1 The 2015 review of the same group states that GHK "is capable of up- and downregulating at least 4,000 human genes".3 Pickart and Margolina write that the Broad Institute's Connectivity Map "allowed researchers to investigate genome-wide effects of GHK" and, in their account of work by Hong and colleagues, describe it as holding expression profiles evaluated in five cancer cell lines in response to 1,309 bioactive small molecules.1 Neither review states in these passages which dataset the 31.2% and 4,000 figures come from, and both reviews are by the same group (Skin Biology).1,3
Campbell and colleagues (Genome Medicine, 2012) used the Connectivity Map on a gene-expression signature of emphysema-related lung destruction (127 genes, from 64 lung samples, 8 regions from each of 8 lungs of smokers with COPD) and identified GHK as a compound that can reverse it.9
In animals
In a rat wound model, repeated GHK-Cu injections of 2 mg stimulated wound tissue production and raised decorin mRNA while lowering biglycan mRNA (Siméon and colleagues, Journal of Investigative Dermatology, 2000).10 In 72 rats after anterior cruciate ligament reconstruction, weekly intra-articular GHK-Cu injections for 4 weeks (0.3 or 3 mg/ml) were followed by a smaller side-to-side knee laxity difference than saline at 6 weeks (p = 0.009), but not at 12 weeks, with no significant difference in ultimate load, gait parameters or histological scores among the treatment groups (Fu and colleagues, Journal of Orthopaedic Research, 2015).11 The authors conclude that the beneficial effects could not last as treatment discontinued.11
Pharmacokinetics
Values from the Milligram app's model.
- Half-life
- ~4 h
- Bioavailability
- 95%
- Typical dose
- 1–3 mg/day
- Route
- SubQ, topical
- Time to peak
- ~0.5 h
A search of PubMed on 16 November 2026 for GHK-Cu, copper tripeptide or glycyl-L-histidyl-L-lysine with pharmacokinetic or half-life in the title or summary, limited to records indexed with the MeSH term Humans (recent records not yet indexed would not appear), returned 0 records. Mateescu and colleagues, in Pharmaceutics in 2026, state that formal absorption, distribution, metabolism and excretion studies of the intact complex "have not been reported".2 The same review writes that, as a small tripeptide that is a substrate for aminopeptidases and dipeptidyl peptidases, free GHK "is therefore expected to have a short systemic half-life".2
In rats given a single intravenous dose, Endo and colleagues (Journal of Chromatography B, 1997) report that "GHK was rapidly degraded to HK, which was eliminated rapidly", where HK is the metabolite L-histidyl-L-lysine.12 The published summary of that study gives no half-life value.12 Pickart and Margolina state, in a wound-healing passage that cites no study for it, that GHK-Cu "is very sensitive to breakdown by carboxypeptidase enzymes" and that the "wound serum" of wounds such as diabetic skin ulcers or bedsores rapidly breaks down GHK.1
For skin, Hostynek and colleagues (Inflammation Research, 2011) applied 0.68% aqueous copper tripeptide to isolated human skin layers and measured copper by inductively coupled plasma mass spectrometry over 48 hours, so copper, not intact peptide, was measured.13 Through dermatomed skin, 136.2 ± 17.5 μg/cm2 of copper permeated over 48 h (2.0 ± 0.31% of the applied dose; n = 8 skin samples from cadaver skin stored frozen), and 97 ± 6.6 μg/cm2 was retained as depot.13 Through isolated epidermis (n = 3), 0.006 ± 0.001% of the dose permeated, and through isolated stratum corneum (n = 3), 2,110 ± 589 μg/cm2 (19.85 ± 3.9% of the dose), so the three layers differ widely.13
| Measure | App figure | What the studies report |
|---|---|---|
| Half-life | ~4 h | No human half-life is reported in the studies cited here or in a query limited to records indexed with the MeSH term Humans (0 records); a rat intravenous study reports rapid degradation to HK, and its published summary gives no half-life value.12,2 |
| Bioavailability | 95% | No bioavailability figure is reported in the studies cited here. In an in vitro topical test on frozen cadaver skin, copper (not intact peptide) was measured: 2.0 ± 0.31% of the applied dose permeated dermatomed skin over 48 h (n = 8) and 97 ± 6.6 μg/cm2 was retained in the skin; neither is a bioavailability figure.13 |
| Time to peak | ~0.5 h | No human plasma time course is reported in the studies cited here. |
| Duration of action | ~8 h | No duration of action is stated in the studies cited here. |
| Plasma level of GHK | Not an app figure | About 200 ng/mL at age 20 and 80 ng/mL by age 60, as stated in a 2015 review that gives no sex, method or number of people; a 2012 review by the same authors gives men aged 20 to 25 and 60 to 80.3,4 |
Human studies
Two randomised trials with wrinkle or resurfacing outcomes are summarised from their own reports below, both of topical products: a trial of 40 women with a facial serum and a trial of 13 patients after laser resurfacing.8,14 A third randomised, double-blind split-face study of 18 participants with a nominal 2% GHK-Cu serum, on eyebrow hair (Bo and colleagues, 2026), is listed from a 2026 review's table.2 A phase 2 trial of a topical gel on standardised wounds was listed as recruiting at its February 2026 registry verification.15
| Study and year | Design | People | Dose and length | Main result |
|---|---|---|---|---|
| Badenhorst and colleagues, 20168 | Randomised, double-blind, split-face; funded by Snowberry New Zealand Ltd with Callaghan Innovation | 40 women aged 40 to 65; 39 in the percentage-change table | GHK-Cu in a lipid nano-carrier serum twice daily, 8 weeks; one wrinkle at the corner of the eye measured per person | Wrinkle volume reduced by 31.6% more than with a Matrixyl 3000 product (p=0.004; n=19 per arm); against a control serum (n=20 per arm), a relative reduction of 55.8% in volume (p<0.001) and 32.8% in depth (p=0.012); the 23.4% greater reduction in depth against the Matrixyl 3000 product had p=0.0577. |
| Miller and colleagues, 200614 | Randomised, blinded evaluators; patients had circumoral CO2 laser resurfacing | 13 patients completed | Post-treatment skin regimen with or without GHK-Cu; questionnaire at 12 weeks | No significant difference in erythema resolution; no difference between groups in wrinkles or overall skin quality; questionnaire improvement in overall skin quality favoured GHK-Cu (P = .04). |
| Bo and colleagues, 2026, as listed in a 2026 review2 | Randomised, double-blind, vehicle-controlled, split-face | 18 healthy participants | Nominal 2% GHK-Cu serum; results at 12 weeks | Outcomes were eyebrow hair count, diameter, photographic assessment and satisfaction; the review lists improvement on the treated side at 12 weeks and no serious adverse events reported, says the study "did not define GHK-Cu speciation or local exposure" and calls it "a small single-center study with a cosmetic endpoint and chemically undercharacterized test material"; the review's table gives no sponsor or funding. |
| Hudson Biotech, NCT07437586, registered 202615 | Phase 2, randomised, double-blind, vehicle-controlled, split-wound; listed as recruiting in February 2026 | 60 healthy adults aged 18 to 55 planned | 0.1% w/w gel once daily for 14 days; follow-up to week 12 | No results posted; primary outcome is time to complete re-epithelialization, over 21 days. |
Pickart and Margolina's 2018 review also summarises a 12-week facial cream study in 71 women and a 12-week eye cream study in 41 women, citing American Academy of Dermatology meeting proceedings.1 Najafi and colleagues write that the 2002 facial-cream and eye-cream reports were published only at conferences and "have not appeared in full peer-reviewed form".5 Mateescu and colleagues describe the facial-cream report by Leyden and colleagues as "a conference-level cosmetic report rather than a fully reported controlled trial".2
Deeper analysis: Badenhorst and colleagues, 2016
The study came from the School of Pharmacy at the University of Auckland, and the trial itself was run at Dermatest GmbH, a cosmetic research institute in Münster.8 Each volunteer applied the GHK-Cu serum twice daily to the right side of the face and, to the left side, either a Matrixyl 3000 product (group 1) or a control serum without GHK-Cu or nano-carrier (group 2).8 One large wrinkle near the corner of the eye was measured per volunteer for depth and volume, at 4 weeks (serum and Matrixyl 3000 product) and 8 weeks (all three).8
At 8 weeks the serum reduced wrinkle volume by 31.6% more than the Matrixyl 3000 product (p=0.004; n=19 per arm), while the 23.4% greater reduction in wrinkle depth against it had p=0.0577.8 Against the control serum (n=20 per arm), wrinkle volume fell 24.1% from baseline with the serum and 15.0% with the control, a relative reduction of 55.8% (p<0.001), and wrinkle depth fell 20.3% against 15.3%, a relative reduction of 32.8% (p=0.012).8 The control serum contained neither GHK-Cu nor the nano-carrier, so the comparison does not separate the two.8
Snowberry New Zealand Limited provided the serum, and the paper states that Snowberry "had no involvement in the collection, analysis, interpretation of data, decision to submit or in the writing of this article".8 The article has no separate limitations section, the control serum was measured at 8 weeks only, and the strength of GHK-Cu in the serum is not stated in the text.8 The authors attribute the result to the delivery system, writing that "it was the nano-carrier that impacted significantly on the total wrinkle reduction and not the formulation".8
Deeper analysis: Miller and colleagues, 2006
Miller and colleagues (Archives of Facial Plastic Surgery, 2006) randomised patients who had circumoral skin resurfacing with a CO2 laser to post-treatment skin regimens with or without GHK-Cu.14 Thirteen patients completed the study, and "Computer analysis and blinded evaluators found no statistically significant differences between groups for earlier resolution of erythema".14 The results state that all patients had significant improvement in wrinkles and overall skin quality with no difference between groups, while the questionnaire showed a significant difference in posttreatment improvement of overall skin quality for those using GHK-Cu (P = .04).14 The conclusion states that objective evaluation "found no significant improvement in wrinkles or overall skin quality" while "patient satisfaction was significantly higher for those who used GHK-Cu skin care products".14 Mateescu and colleagues add that "A trial of this size cannot exclude a moderate effect" and that the products' active content was not characterized.2 The published summary gives no funding statement or limitations passage.14
Doses reported in studies
| Study | Dose or strength | Route and frequency | Length | Who |
|---|---|---|---|---|
| Badenhorst and colleagues, 20168 | Strength not stated in the text | Topical serum on facial skin, twice daily | 8 weeks | 40 women aged 40 to 65 |
| Miller and colleagues, 200614 | Strength not stated in the summary | Topical skin care regimen after laser resurfacing | Regimen length not stated in the summary; outcomes assessed at 12 weeks | 13 patients completed |
| NCT07437586, 202615 | 0.1% w/w gel, a thin film of approx. 0.5 g | Topical, once daily to the assigned wound | 14 days | 60 healthy adults planned |
Sources in this part
None of the studies in the table gives an injected human dose, while the app's typical dose is 1 to 3 mg per day.
Side effects reported
In the Auckland trial the products were "well tolerated by 39 of the 40 subjects", and one participant had minor unwanted skin reactions on both sides of the face after the serum and the Matrixyl 3000 product that resolved without medical treatment after application stopped.8
Pickart, Vasquez-Soltero and Margolina write in 2015 that "The molecule is very safe and no issues have ever arisen during its use as a skin cosmetic or in human wound healing studies".3 That statement is made by authors at Skin Biology, whose concentration of authorship Najafi and colleagues, in a separate passage, say limits the independence of the evidence base of the GHK-Cu literature as a whole.3,6
FDA's entry for GHK-Cu for injectable routes states that compounded injectable drugs containing GHK-Cu "may pose risk for immunogenicity due to the potential for aggregation and peptide-related impurities" and that "There are limited data in humans to inform safety-related considerations".16 The Therapeutic Goods Administration's April 2026 advisory on unapproved peptide products, which lists products containing GHK-Cu among its examples, sets out adverse events and other concerns received for these products as a group in six categories, including severe allergic reactions requiring adrenaline and hospitalisation and systemic inflammatory response syndrome requiring hospital management.17
Bloodwork and markers
Sources in this part
The 2012 review's levels are stated for men aged 20 to 25 and at age 60 to 80, while the 2015 and 2018 reviews of the same authors give them at age 20 and by age 60 without stating sex, method or number of people, so the stated age ranges differ.4,3,1
A registered study (NCT07706361) sponsored by LifeWave, with KGK Science as collaborator, was listed as not yet recruiting at its July 2026 verification, with an estimated start in January 2027. It has two parts, a single-arm open-label Part 1 and a randomised, double-blind, placebo-controlled Part 2, and plans to measure the change in GHK and GHK-Cu blood levels from baseline to day 8 in an estimated 100 healthy adults, comparing the sponsor's X39 skin patch with a placebo patch. The registry lists the X39 patch as a device and does not describe its contents.18
Regulatory and anti-doping status
FDA's page on bulk drug substances nominated for section 503A compounding, updated 14 May 2026, states that "GHK-Cu (except for injectable routes of administration)" was removed from category 1 (FDA's list of "Bulk Drug Substances Under Evaluation") on April 22, 2026 "because the nominations for GHK-Cu were withdrawn by the nominators".19 It adds that on May 5, 2026 one of those nominators "clarified that it intended to withdraw only its nomination of the injectable route of administration", so GHK-Cu (except for injectable routes of administration) "will be added back to category 1".19 FDA also states that it "has announced it intends to consult the Pharmacy Compounding Advisory Committee (PCAC) before the end of February 2027 regarding the potential inclusion of GHK-Cu on the 503A bulks list".19
FDA's page on bulk drug substances that may present significant safety risks, current as of 22 April 2026, lists GHK-Cu (for injectable routes of administration) under substances nominated but withdrawn.16
The Therapeutic Goods Administration's safety advisory of 13 April 2026 lists products containing GHK-Cu among its examples of unapproved peptide products, "often supplied in injectable form".17 The advisory defines unapproved peptide products as "goods which have not been included in the ARTG" and states that "These products have not been evaluated for safety, quality or effectiveness by the TGA".17 The advisory does not say whether any GHK-Cu product is on the ARTG and does not address cosmetic products.17
The World Anti-Doping Agency's 2026 Prohibited List, in effect from 1 January 2026, does not name GHK-Cu: a text search of the list for GHK, copper, glycyl and tripeptide returned 0 matches.20 Class S0 covers "Any pharmacological substance which is not addressed by any of the subsequent sections of the List and with no current approval by any governmental regulatory health authority for human therapeutic use", and names BPC-157 among its examples.20 The list text does not say whether GHK-Cu falls under S0.20
What is not known
Sources in this part
A search of PubMed on 16 November 2026 for GHK-Cu, copper tripeptide or glycyl-L-histidyl-L-lysine with injection, injected or subcutaneous in the title or summary, limited to records indexed with the MeSH term Humans (recent records not yet indexed would not appear), returned 1 record. That record is Kapoor and Shome (Journal of Cosmetic and Laser Therapy, 2018), an open-label, single-arm pilot study in which 1000 patients were given intradermal scalp injections of a formulation that contains several growth factors, thymosin β4 and copper tripeptide-1.21 A result in that study is a result of the combined formulation, not of GHK-Cu alone.21
Mateescu and colleagues write that "the evidentiary meaning of 'GHK-Cu' depends on which entity was actually studied", separating GHK without copper, the canonical complex, GHK-derived copper peptides and unrelated copper-peptide systems.2
Mortazavi and colleagues, in a 2025 review of topical anti-wrinkle use, write of a "surprising absence of clinical studies" of GHK-Cu and a palmitoylated derivative for this purpose.22
Frequently asked questions
Sources in this part
What is the half-life of GHK-Cu?
The app lists a half-life of about 4 hours for GHK-Cu. A 2026 review states that formal absorption, distribution, metabolism and excretion studies of the intact complex "have not been reported", and a search of PubMed on 16 November 2026 for human pharmacokinetic or half-life studies returned 0 records.2
What is GHK-Cu?
GHK-Cu is the copper(II) complex of the tripeptide glycyl-L-histidyl-L-lysine.2
Does GHK-Cu occur naturally in the body?
GHK occurs naturally in human plasma, saliva and urine, and a 2015 review puts its plasma level at about 200 ng/mL at age 20 and 80 ng/mL by age 60, without giving the sex, method or number of people measured.3 A 2012 review by the same authors gives about 200 micrograms/liter in men aged 20 to 25 and 80 micrograms/liter at age 60 to 80.4
Is GHK-Cu banned by WADA?
What is GHK-Cu's status on FDA's compounding lists?
FDA's page updated 14 May 2026 states that GHK-Cu (except for injectable routes of administration) will be added back to category 1 of the 503A nominations.19 The injectable route is listed on FDA's safety risks page, current as of 22 April 2026, under bulk drug substances nominated but withdrawn.16
Is GHK-Cu an approved product in Australia?
The Therapeutic Goods Administration's April 2026 advisory lists products containing GHK-Cu among its examples of unapproved peptide products, which it defines as goods not included in the ARTG, and does not say whether any GHK-Cu product is on the ARTG or address cosmetic products.17
What did the GHK-Cu wrinkle trial in 40 women find?
In Badenhorst and colleagues' 8-week randomised trial of 40 women, a GHK-Cu nano-carrier serum reduced wrinkle volume by 31.6% more than a Matrixyl 3000 product (p=0.004) and by a relative 55.8% against a control serum (p<0.001).8 The depth difference against the Matrixyl 3000 product had p=0.0577, and the trial was funded by Snowberry New Zealand Ltd in collaboration with Callaghan Innovation.8
Did GHK-Cu improve skin after laser resurfacing?
In Miller and colleagues' randomised trial of 13 patients, objective evaluation found no significant improvement in wrinkles or overall skin quality, while patient satisfaction was significantly higher for those who used GHK-Cu products (P = .04 on the overall skin quality questionnaire item).14
How much copper passed through human skin samples in the one in vitro study?
In an in vitro study of dermatomed human skin from frozen cadavers, 136.2 ± 17.5 μg/cm2 of copper permeated over 48 h (2.0 ± 0.31% of the applied dose; n = 8) from a 0.68% aqueous copper tripeptide solution, and 97 ± 6.6 μg/cm2 was retained as depot.13 Through isolated stratum corneum (n = 3), 19.85 ± 3.9% of the dose permeated, and through isolated epidermis (n = 3), 0.006 ± 0.001%, so the three layers differ widely.13 Copper, not intact peptide, was measured, and Mateescu and colleagues note that detection of total copper in the receptor compartment "does not demonstrate that the intact complex crossed the barrier".2
Guides, tools and comparisons
- GHK-Cu injection dosageA guide that answers a question on this compound.
- Calculator for GHK-CuA calculator set up for this compound.
- GHK-Cu vs AHK-CuA side-by-side with another compound.
- Previous in Cosmetic and copper peptides: GHK (Tripeptide-1)The compound before this one in the class.
- Next in Cosmetic and copper peptides: KPV + GHK-CuThe compound after this one in the class.
References
- Pickart L, Margolina A. Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data. Int J Mol Sci 2018. PMC6073405
- Mateescu DM, et al. GHK-Cu as a Bioactive Metallopeptide and Drug-Delivery Cargo: Coordination Chemistry, Formulation Science, Therapeutic Evidence, and a Translational Roadmap. Pharmaceutics 2026. PMC13610439
- Pickart L, Vasquez-Soltero JM, Margolina A. GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration. Biomed Res Int 2015. PMC4508379
- Pickart L, Vasquez-Soltero JM, Margolina A. The Human Tripeptide GHK-Cu in Prevention of Oxidative Stress and Degenerative Conditions of Aging: Implications for Cognitive Health. Oxid Med Cell Longev 2012. PMC3359723
- Najafi N, et al. A Systematic Review of the Mechanisms and Therapeutic Applications of GHK-Cu in Topical Microneedle Delivery: A Case for Expanded Clinical Trials. Arch Intern Med Res 2026. PMC13604022
- Mokhtar J, et al. The Regenerative Potential of GHK-Cu in Aesthetic Medicine. Aesthet Surg J 2026. PMID 42619529
- Pickart L, Freedman JH, Loker WJ, et al. Growth-modulating plasma tripeptide may function by facilitating copper uptake into cells. Nature 1980. PMID 7453802
- Badenhorst T, Svirskis D, Merrilees M, Bolke L, Wu Z. Effects of GHK-Cu on MMP and TIMP Expression, Collagen and Elastin Production, and Facial Wrinkle Parameters. J Aging Sci 2016. Full text (PDF)
- Campbell JD, et al. A gene expression signature of emphysema-related lung destruction and its reversal by the tripeptide GHK. Genome Med 2012. PMID 22937864
- Siméon A, Wegrowski Y, Bontemps Y, Maquart FX. Expression of glycosaminoglycans and small proteoglycans in wounds: modulation by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu(2+). J Invest Dermatol 2000. PMID 11121126
- Fu SC, et al. Tripeptide-copper complex GHK-Cu (II) transiently improved healing outcome in a rat model of ACL reconstruction. J Orthop Res 2015. PMID 25731775
- Endo T, Miyagi M, Ujiie A. Simultaneous determination of glycyl-L-histidyl-L-lysine and its metabolite, L-histidyl-L-lysine, in rat plasma by high-performance liquid chromatography with post-column derivatization. J Chromatogr B Biomed Sci Appl 1997. PMID 9187381
- Hostynek JJ, Dreher F, Maibach HI. Human skin penetration of a copper tripeptide in vitro as a function of skin layer. Inflamm Res 2011. PMC3016279
- Miller TR, Wagner JD, Baack BR, Eisbach KJ. Effects of topical copper tripeptide complex on CO2 laser-resurfaced skin. Arch Facial Plast Surg 2006. PMID 16847171
- Hudson Biotech. Topical GHK-Cu Gel for Acute Skin Wound Healing. ClinicalTrials.gov NCT07437586, 2026. NCT07437586
- US Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. Content current as of 22 April 2026. FDA safety risks page
- Therapeutic Goods Administration. Understanding your responsibilities when importing, compounding and supplying unapproved peptide products. Safety advisory, 13 April 2026. TGA safety advisory
- LifeWave, Inc. Two-Part Study of the Effects of the X39 Patch on Circulating GHK and GHK-Cu Levels in Healthy Adults. ClinicalTrials.gov NCT07706361, 2026. NCT07706361
- US Food and Drug Administration. Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act. Updated 14 May 2026. FDA 503A nominations
- World Anti-Doping Agency. World Anti-Doping Code International Standard Prohibited List 2026. WADA Prohibited List 2026
- Kapoor R, Shome D. Intradermal injections of a hair growth factor formulation for enhancement of human hair regrowth - safety and efficacy evaluation in a first-in-man pilot clinical study. J Cosmet Laser Ther 2018. PMID 29482481
- Mortazavi SM, et al. Topically applied GHK as an anti-wrinkle peptide: Advantages, problems and prospective. Bioimpacts 2025. PMID 39963574